|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Decitabine and its role in the treatment of hematopoietic malignancies显示文摘 | Plimack ER Kantarjian HM Issa JP | 2007 | Leuk Lymphoma2007，48，8： | 1 |
| 2 | Phase Istudy of nivolumab in combination with ipilimumab (IPI) inmetastatic renal cell carcinoma (mRCC) 显示文摘 | HAMMERS H PLIMACK ER INFANTE JR | 2014 | BJU Int2014，114，111： | 1 |
| 3 | A phase I b multi-cohort study of MK-3472 in subject with advanced solid tumors显示文摘 | Plimack ER Bellmunt J Gupta S | 2015 | J Clin Oncol2015，33，： | 1 |
| 4 | Immune checkpoint blockade as a novel immunotherapeutic strategy for renal cell carcinoma: a review of clinical trials显示文摘 | GODWIN JL ZIBELMAN M PLIMACK ER | 2014 | Discov Med2014，18，101： | 1 |
| 5 | Prolonged topotecan infusion wish cisplatin in the firt-line treatment of ovarian cancer:An NYGOG and ECOG study显示文摘 | Hoochster HS Plimack ER Mandeli J | 2006 | Gynecol Oncol2006，100，2： | 1 |
| 6 | Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle - invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity 显示文摘 | Plimack ER Hoffman - Censits JH Viterbo R | 2014 | J Clin Oncol2014，32，18： | 1 |
| 7 | Decitabine and its role in the treatment of hematopoietic malignancies显示文摘 | Plimack ER Kantarjian HM Issa JP | 2007 | Leuk Lymphoma2007，48，8： | 1 |
| 8 | Combining epigenetic and cy- totoxic therapy in the treatment of solid tumors显示文摘 | Plimack ER Stewart DJ Issa JP | 2007 | J Cli Oncol2007，25，29： | 1 |
| 9 | Lymphopenia is an inde- pendent predictor of inferior outcome in clear cell renal carcinoma 显示文摘 | Saroha S Uzzo ]RG Plimack ER | 2013 | The J urology2013，，： | 1 |
| 10 | A phase I study of temsirolim- us and bryostatin- 1 in patients with metastatic renal cell carcinoma and soft tissue sarcoma显示文摘 | Plimack ER Tan T Wong YN | 2014 | Oncologist2014，19，4： | 1 |
| 11 | Decitabine and its role inthe treatment of hematopoietic malignancies显示文摘 | Plimack ER Kantarjian HM Issa JP | 2007 | Leuk Lymphoma2007，48，8： | 1 |
| 12 | Nivolumab (anti - PD - 1 ; BMS -936558,ONO -4538) in combination with sunitinib or peizopanib in patients ( pts) with metastatic renal cell carcinoma (mRCC)显示文摘 | Amin A Plimack ER Infante JR | 2014 | J Clin Oncol2014，32，15： | 1 |
| 13 | Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer 显示文摘 | Plimack ER Dunbrack RL Brennan TA | 2015 | Eur Urol2015，68，6： | 1 |
| 14 | Patterns of disease progression in metastatic renal cell carcinoma patients treated with mtivascular agents and interferon:impact of therapy on recurrence patterns and outcome measures 显示文摘 | Plimack ER Tannir N Lin E | 2009 | Cancer2009，115，9： | 1 |
| 15 | Accel- erated methotrexate, vinblastine, doxorubiein, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle - invasive bladder cancer: results of a muhieenter phase II study with molecular correlates of response and tox- icity显示文摘 | Plimack ER Hoffman - Censits JH Viterbo R | 2014 | J Clin Oneol2014，32，18： | 1 |
| 16 | Decitabine and its role in the treatment of hematopoietic malignancies 显示文摘 | Plimack ER Kantarjian HM Issa JP | 2007 | Leuk Lymphoma2007，48，8： | 1 |
| 17 | Sunitinib in non-clear cell renal cell carcinoma: A phase Ⅱ study 显示文摘 | Plimack ER Jonasch E Bekele BN | 2008 | J Clin Oncol2008，，： | 1 |
| 18 | Phase I Dose-Escalation Study of MEDI-573, a Bispecific, Antiligand Monoclonal Antibody against IGF I and IGF Ⅱ , in Patients with Advanced Solid Tumors显示文摘 | Haluska P Menefee M Plimack ER | 2014 | Clin Cancer Res2014，20，18： | 1 |
| 19 | Sunitinib in non-clear cell renal cell carcinoma (ncc-RCC):A phase II study显示文摘 | Plimack ER Jonasch E Bekele BN | 2008 | J Clin Oncol2008，，： | 1 |
| 20 | Lymphopenia is an independent predictor of inferior outcmne in clear cell renal carcinoma显示文摘 | Saroha S Uzzo RG Plimack ER | 2013 | J Urol2013，189，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员